Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 4Neuroblastoma 4Head and Neck Neoplasms 4Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Lymphoma 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms 2Mouth Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Hodgkin Disease 2Burkitt Lymphoma 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Fenretinide × Clear all
NCT00003099 2012-07-30

Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
52 enrolled
Breast

Breast Neoplasms

NCT00002646 2012-01-05

Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer

National Cancer Institute (NCI)

Phase 3 Completed
1,500 enrolled
Breast

Breast Neoplasms

NCT00001378 2008-03-04

A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
75 enrolled
Breast

Breast Neoplasms, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡